



Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 29, 2025-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time.

Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at <http://investor.veracyte.com/events-presentations>. A replay of the webcast will be available for 30 days following the conclusion of the live broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on [LinkedIn](#) or [X \(Twitter\)](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251229651465/en/): <https://www.businesswire.com/news/home/20251229651465/en/>

Investors:

Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:

Karen Possemato
media@veracyte.com

Source: Veracyte, Inc.